PoA = directional probability-of-approval estimate based on public data, historical precedent, and market context. These are internal analytical views — not FDA guidance or statistical predictions.

Top Events Near-Term (Next 2 Weeks)

TransCon CNP (navepegritide) — $ASND ( ▲ 0.98% )

Date: Nov 30
Event: PDUFA (Achondroplasia)
PoA: 80

Setup: FDA accepted the NDA for TransCon CNP with Priority Review. The pivotal ApproaCH trial showed a statistically significant improvement in annualized growth velocity (AGV) compared to placebo in children with achondroplasia.

Our View: High PoA. Strong placebo-controlled efficacy and a clean safety profile. The key watch item is the label, especially growth-velocity language and positioning versus BioMarin's Voxzogo.

Avance® Nerve Graft — $AXGN ( ▲ 1.98% )

Date: Dec 5
Event: PDUFA (Biologic BLA)
PoA: 72

Setup: The FDA extended the PDUFA date to December 5 after accepting a Major Amendment to review additional manufacturing and facility information.

Our View: This is primarily a CMC/quality binary, not a clinical one. Base case is procedural delay and eventual approval; bear case is deeper consistency or facility concerns.

ORLADEYO (berotralstat, oral granules) — $BCRX ( ▲ 1.05% )

Date: Dec 12
Event: PDUFA (Pediatric HAE, 2–11 years)
PoA: 86

Setup: The pediatric NDA was accepted with Priority Review. The current Dec 12 action date reflects a 3-month PDUFA extension from the original September 12 date after BioCryst submitted additional formulation data in June, which FDA classified as a major amendment requiring full review.

Our View: Very high PoA. If approved, ORLADEYO becomes the first oral targeted prophylactic for HAE in children under 12, strengthening the pipeline against injectable competitors.

📆 Event Update (Clarified Timelines)

Bezuclastinib — $COGT ( ▼ 2.47% )

  • PEAK (2L GIST) Phase 3 ToplineResolved (strongly positive, Nov 10).

  • APEX (Advanced Systemic Mastocytosis) → Topline expected December 2025, not November.
    Will appear in a future Pulse once date is confirmed.

Nimacimab — $SKYE ( ▼ 2.5% )

  • Phase 2a topline reported Oct 6: monotherapy failed the primary endpoint (p=0.2699).

  • GLP-1 combination arm remains the only viable bull case.
    Not a November binary.

Resolved Last Week (Nov 17–23)

Plozasiran (REDEMPLO) — $ARWR ( ▼ 0.77% )

Event: PDUFA (FCS)
Outcome: Approved (Nov 18)

Context: FDA approved plozasiran as the first siRNA therapy for familial chylomicronemia syndrome. Phase 3 data showed ~80% median triglyceride reduction and reduced pancreatitis incidence. The market now focuses on pricing, access, and competitive dynamics.

Ziftomenib (KOMZIFTI) — $KURA ( ▼ 1.69% )

Event: PDUFA (originally Nov 30)
Outcome: Approved Early (Nov 13)

Context: Approved for adults with relapsed/refractory AML harboring an NPM1 mutation. The label includes a Boxed Warning for differentiation syndrome — the key gating issue in the regulatory debate. Efficacy is validated; commercial risk centers on DS management and adoption in real-world oncology settings.

Mitapivat (PYRUKYND) — $AGIO ( ▼ 3.07% )

Event: Phase 3 Topline — RISE UP
Outcome: Mixed (Nov 19)

Context: Met the hemoglobin-response primary endpoint and key hemolysis secondaries, but failed the co-primary endpoint of annual sickle cell pain crises and failed the PROMIS fatigue endpoint. Biology is intact; the commercial thesis took a hit. The 50% pre-data drawdown now looks like informed de-risking around the trial’s ability to meet the crises endpoint.

📊 PoA Framework (Snapshot)

PoA Bands:

  • High: >70

  • Moderate: 40–70

  • Speculative: <40

Five-Factor Model:

  1. Study design

  2. Data strength

  3. Safety / CMC

  4. Regulatory precedent

  5. Sponsor execution

Directional only; always pair PoA with context on trial design, division history, and tape behavior.

Keep Reading

No posts found